PubMed Health⌕ Search

PubMed · 11759561

Transmyocardial laser revascularization.

Abstract

In transmyocardial laser revascularization, a small left thoracotomy incision is made at the fifth rib. The surgeon dissects until adequate exposure of the heart is made, and the laser can be used. The areas to be lasered are identified, and treatment begins. As each laser beam penetrates the myocardium, a flash of bubbles can be seen on echocardiogram exiting the left ventricular outflow tract, which confirms adequate channeling. After revascularization, the mitral valve is inspected for any damage to papillary muscle or leaflets. This case report focuses on a new laser procedure that creates channels in the heart that promote angiogenesis and reestablish blood flow. A 47-year-old man presented for this surgery after having previous coronary artery bypass surgery. He had worsening angina and was not recommended for repeat bypass surgery because of his diffuse disease. Transmyocardial laser revascularization was offered as an alternative to medical therapy. Complications reported include dysrhythmia, bleeding, congestive heart failure, mitral valve damage, low cardiac output syndrome, and death. Many patients note substantial anginal relief after a few weeks. Transmyocardial laser revascularization gives an alternative to those with intractable angina and generally offers an improvement in quality of life.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M W Bernheim. 2001. Transmyocardial laser revascularization.. https://pubmed.ncbi.nlm.nih.gov/11759561/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗